Recovery of chronic central serous chorioretinopathy with a single dose of intravitreal ranibizumab injection: A case report

Abstract

Central serous chorioretinopathy is an idiopathic condition characterized by the development of a serous detachment of the sensory retina especially in healthy men between 25 and 55 years of age. Observation of the patients at least for three months for spontaneous recovery in unilateral central serous chorioretinopathy is recommended. Conventional treatment modalities include laser photocoagulation and photodynamic therapy but these treatments can cause permanent damage to the retinal pigment epithelium or choriocapillary. Recently intravitreal anti-vascular endothelial growth factor agents have been used to ameliorate this condition but their results are contraversial. Herein we present a succesful treatment of a patient with chronic central serous chorioretinopathy with a single dose of intravitreal ranibizumab injection. 

Keywords

• Central serous chorioretinopathy; Choroidal thickness; Photodynamic therapy; Ranibizumab